IMImmunovant IMVT · NASDAQ
$29.42 +1.87% (+$0.54)
- Market cap
- $6.08B
- Enterprise value
- $5.28B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 856.5x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -75.9%
- Gross margin
- 97.1%
- Net margin
- -7,585.9%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.84
- Free float
- 41.1%
About the company
Immunovant, Inc. is an American biotechnology company focused on the development of innovative immunotherapies for the treatment of autoimmune diseases. The company specializes in the development of monoclonal antibodies that target specific immune pathways, which can help patients suffering from conditions such as myasthenia gravis, autoimmune hemolytic anemia, and others. Immunovant aims to provide effective therapeutic options for patients whose current treatments are insufficient or associated with undesirable side effects.
Sector
Healthcare
Industry
Biotechnology
CEO
Eric Venker
Employees
315
Headquarters
Durham
Valuation
Is today's price reasonable?
- What to watch: The share price is above the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What to watch: It missed profit estimates 5 times in the last 8 quarters.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
- What speaks for it: It has no debt and holds $797.8M in cash.
- What to watch: It passes only 3 of the 9 points of the Piotroski financial health test.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number